US633410A
(en)
|
1898-09-22 |
1899-09-19 |
George A Ames |
Ice-cutter.
|
US3896111A
(en)
|
1973-02-20 |
1975-07-22 |
Research Corp |
Ansa macrolides
|
IL47062A
(en)
|
1975-04-10 |
1979-07-25 |
Yeda Res & Dev |
Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
|
US4151042A
(en)
|
1977-03-31 |
1979-04-24 |
Takeda Chemical Industries, Ltd. |
Method for producing maytansinol and its derivatives
|
US4137230A
(en)
|
1977-11-14 |
1979-01-30 |
Takeda Chemical Industries, Ltd. |
Method for the production of maytansinoids
|
US4307016A
(en)
|
1978-03-24 |
1981-12-22 |
Takeda Chemical Industries, Ltd. |
Demethyl maytansinoids
|
US4265814A
(en)
|
1978-03-24 |
1981-05-05 |
Takeda Chemical Industries |
Matansinol 3-n-hexadecanoate
|
JPS5562090A
(en)
|
1978-10-27 |
1980-05-10 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
US4256746A
(en)
|
1978-11-14 |
1981-03-17 |
Takeda Chemical Industries |
Dechloromaytansinoids, their pharmaceutical compositions and method of use
|
JPS5566585A
(en)
|
1978-11-14 |
1980-05-20 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
JPS55164687A
(en)
|
1979-06-11 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
JPS55102583A
(en)
|
1979-01-31 |
1980-08-05 |
Takeda Chem Ind Ltd |
20-acyloxy-20-demethylmaytansinoid compound
|
US4665077A
(en)
|
1979-03-19 |
1987-05-12 |
The Upjohn Company |
Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
|
JPS55162791A
(en)
|
1979-06-05 |
1980-12-18 |
Takeda Chem Ind Ltd |
Antibiotic c-15003pnd and its preparation
|
JPS55164685A
(en)
|
1979-06-08 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
JPS55164686A
(en)
|
1979-06-11 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
US4309428A
(en)
|
1979-07-30 |
1982-01-05 |
Takeda Chemical Industries, Ltd. |
Maytansinoids
|
JPS5645483A
(en)
|
1979-09-19 |
1981-04-25 |
Takeda Chem Ind Ltd |
C-15003phm and its preparation
|
JPS5645485A
(en)
|
1979-09-21 |
1981-04-25 |
Takeda Chem Ind Ltd |
Production of c-15003pnd
|
EP0028683A1
(fr)
|
1979-09-21 |
1981-05-20 |
Takeda Chemical Industries, Ltd. |
Antibiotique C-15003 PHO et sa préparation
|
WO1981001145A1
(fr)
|
1979-10-18 |
1981-04-30 |
Univ Illinois |
Medicaments "pro-drugs" pouvant etre actives par des enzymes hydrolytiques
|
WO1982001188A1
(fr)
|
1980-10-08 |
1982-04-15 |
Takeda Chemical Industries Ltd |
Composes 4,5-deoxymaytansinoide et leur procede de preparation
|
US4450254A
(en)
|
1980-11-03 |
1984-05-22 |
Standard Oil Company |
Impact improvement of high nitrile resins
|
US4315929A
(en)
|
1981-01-27 |
1982-02-16 |
The United States Of America As Represented By The Secretary Of Agriculture |
Method of controlling the European corn borer with trewiasine
|
US4313946A
(en)
|
1981-01-27 |
1982-02-02 |
The United States Of America As Represented By The Secretary Of Agriculture |
Chemotherapeutically active maytansinoids from Trewia nudiflora
|
JPS57192389A
(en)
|
1981-05-20 |
1982-11-26 |
Takeda Chem Ind Ltd |
Novel maytansinoid
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US4737456A
(en)
|
1985-05-09 |
1988-04-12 |
Syntex (U.S.A.) Inc. |
Reducing interference in ligand-receptor binding assays
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
DE3883899T3
(de)
|
1987-03-18 |
1999-04-22 |
Sb2 Inc |
Geänderte antikörper.
|
IL89220A
(en)
|
1988-02-11 |
1994-02-27 |
Bristol Myers Squibb Co |
Immunoconjugates of anthracycline, their production and pharmaceutical preparations containing them
|
IL85746A
(en)
|
1988-03-15 |
1994-05-30 |
Yeda Res & Dev |
Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
|
FI891226A
(fi)
|
1988-04-28 |
1989-10-29 |
Univ Leland Stanford Junior |
Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom.
|
EP0368684B2
(fr)
|
1988-11-11 |
2004-09-29 |
Medical Research Council |
Clonage de séquences d'immunoglobulines de domaines variables.
|
WO1990008187A1
(fr)
|
1989-01-19 |
1990-07-26 |
Dana Farber Cancer Institute |
Proteine cd2 soluble a deux domaines
|
RO110397B1
(ro)
|
1989-03-21 |
1996-01-30 |
Immune Response Corp San Diego |
Vaccin pentru prevenirea sau tratarea unor boli care rezulta din raspunsuri patogene, prin populatii de celule t specifice, procedeu de obtinere si metode de diagnostic si tratament cu acesta
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
DE69031919T3
(de)
|
1989-07-19 |
2005-01-27 |
Connetics Corp., Palo Alto |
T-zell-rezeptor-peptide als heilmittel für autoimmune und bösartige krankheiten
|
WO1991003493A1
(fr)
|
1989-08-29 |
1991-03-21 |
The University Of Southampton |
CONJUGUES F(ab)3 ou F(ab)4 bi ou trispécifiques
|
CA2026147C
(fr)
|
1989-10-25 |
2006-02-07 |
Ravi J. Chari |
Agents cytotoxiques comprenant des maytansinoides et leur usage therapeutique
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
US5959177A
(en)
|
1989-10-27 |
1999-09-28 |
The Scripps Research Institute |
Transgenic plants expressing assembled secretory antibodies
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
ES2113940T3
(es)
|
1990-12-03 |
1998-05-16 |
Genentech Inc |
Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
LU91067I2
(fr)
|
1991-06-14 |
2004-04-02 |
Genentech Inc |
Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
|
GB9114948D0
(en)
|
1991-07-11 |
1991-08-28 |
Pfizer Ltd |
Process for preparing sertraline intermediates
|
US7018809B1
(en)
|
1991-09-19 |
2006-03-28 |
Genentech, Inc. |
Expression of functional antibody fragments
|
US5362852A
(en)
|
1991-09-27 |
1994-11-08 |
Pfizer Inc. |
Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties
|
US5587458A
(en)
|
1991-10-07 |
1996-12-24 |
Aronex Pharmaceuticals, Inc. |
Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
|
WO1993008829A1
(fr)
|
1991-11-04 |
1993-05-13 |
The Regents Of The University Of California |
Compositions induisant la destruction de cellules infectees par l'hiv
|
DE69334255D1
(de)
|
1992-02-06 |
2009-02-12 |
Novartis Vaccines & Diagnostic |
Marker für Krebs und biosynthetisches Bindeprotein dafür
|
ZA932522B
(en)
|
1992-04-10 |
1993-12-20 |
Res Dev Foundation |
Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
|
EP1005870B1
(fr)
|
1992-11-13 |
2009-01-21 |
Biogen Idec Inc. |
Application thérapeutique d'anticorps chimériques et radio-marqués contre l'antigène à différentiation restreinte des lymphocytes B humains pour le traitement du lymphome des cellules B
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
EP0714409A1
(fr)
|
1993-06-16 |
1996-06-05 |
Celltech Therapeutics Limited |
Anticorps
|
ATE282630T1
(de)
|
1993-10-01 |
2004-12-15 |
Teikoku Hormone Mfg Co Ltd |
Dolastatin-derivate
|
US5773001A
(en)
|
1994-06-03 |
1998-06-30 |
American Cyanamid Company |
Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
|
US5798100A
(en)
|
1994-07-06 |
1998-08-25 |
Immunomedics, Inc. |
Multi-stage cascade boosting vaccine
|
US5789199A
(en)
|
1994-11-03 |
1998-08-04 |
Genentech, Inc. |
Process for bacterial production of polypeptides
|
US5663149A
(en)
|
1994-12-13 |
1997-09-02 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
US5840523A
(en)
|
1995-03-01 |
1998-11-24 |
Genetech, Inc. |
Methods and compositions for secretion of heterologous polypeptides
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
US5712374A
(en)
|
1995-06-07 |
1998-01-27 |
American Cyanamid Company |
Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
GB9603256D0
(en)
|
1996-02-16 |
1996-04-17 |
Wellcome Found |
Antibodies
|
GB2315067B
(en)
|
1996-07-11 |
2000-02-16 |
Pharmacia Spa |
Morpholinyl anthracycline derivatives
|
US5852129A
(en)
|
1996-11-28 |
1998-12-22 |
Kaneka Corporation |
Method for producing hydroxyl-terminated (meth) acrylic polymer
|
EP0979281B1
(fr)
|
1997-05-02 |
2005-07-20 |
Genentech, Inc. |
Procede de preparation d'anticorps multispecifiques presentant des composants heteromultimeres
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
PT994903E
(pt)
|
1997-06-24 |
2005-10-31 |
Genentech Inc |
Metodos e composicoes para glicoproteinas galactosiladas
|
US6040498A
(en)
|
1998-08-11 |
2000-03-21 |
North Caroline State University |
Genetically engineered duckweed
|
US6602677B1
(en)
|
1997-09-19 |
2003-08-05 |
Promega Corporation |
Thermostable luciferases and methods of production
|
AU759779B2
(en)
|
1997-10-31 |
2003-05-01 |
Genentech Inc. |
Methods and compositions comprising glycoprotein glycoforms
|
US6610833B1
(en)
|
1997-11-24 |
2003-08-26 |
The Institute For Human Genetics And Biochemistry |
Monoclonal human natural antibodies
|
BR9813365A
(pt)
|
1997-12-05 |
2004-06-15 |
Scripps Research Inst |
Método para produção e humanização de um anticorpo monoclonal de rato
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
JP2002510481A
(ja)
|
1998-04-02 |
2002-04-09 |
ジェネンテック・インコーポレーテッド |
抗体変異体及びその断片
|
ATE458007T1
(de)
|
1998-04-20 |
2010-03-15 |
Glycart Biotechnology Ag |
Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität
|
CN100531798C
(zh)
|
1998-08-11 |
2009-08-26 |
拜奥根Idec公司 |
包括施用抗-cd20抗体的b-细胞淋巴瘤联合疗法
|
GB9818731D0
(en)
|
1998-08-27 |
1998-10-21 |
Univ Portsmouth |
Compounds
|
PT1193270E
(pt)
|
1998-08-27 |
2003-10-31 |
Spirogen Ltd |
Pirrolobenzodiazepinas
|
DK1616572T3
(da)
|
1998-11-09 |
2010-12-06 |
Biogen Idec Inc |
Kimært anti-CD20-antistof, rituxan, til anvendelse i behandling af kronisk lymfatisk leukæmi
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
PL209786B1
(pl)
|
1999-01-15 |
2011-10-31 |
Genentech Inc |
Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
|
EP2264166B1
(fr)
|
1999-04-09 |
2016-03-23 |
Kyowa Hakko Kirin Co., Ltd. |
Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
|
US7125978B1
(en)
|
1999-10-04 |
2006-10-24 |
Medicago Inc. |
Promoter for regulating expression of foreign genes
|
WO2001025454A2
(fr)
|
1999-10-04 |
2001-04-12 |
Medicago Inc. |
Procede de regulation de la transcription de genes etrangers
|
US7504256B1
(en)
|
1999-10-19 |
2009-03-17 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for producing polypeptide
|
US20030180714A1
(en)
|
1999-12-15 |
2003-09-25 |
Genentech, Inc. |
Shotgun scanning
|
PT1242438E
(pt)
|
1999-12-29 |
2007-02-28 |
Immunogen Inc |
Agentes citotóxicos compreendendo dixorrubicinas e daunorrubicinas modificadas e seu uso terapêutico
|
HUP0300369A2
(hu)
|
2000-04-11 |
2003-06-28 |
Genentech, Inc. |
Többértékű antitestek és alkalmazásuk
|
US6333410B1
(en)
|
2000-08-18 |
2001-12-25 |
Immunogen, Inc. |
Process for the preparation and purification of thiol-containing maytansinoids
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
DK2314686T4
(da)
|
2000-10-06 |
2023-08-21 |
Kyowa Kirin Co Ltd |
Celler, der danner antistofsammensætninger
|
US7064191B2
(en)
|
2000-10-06 |
2006-06-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for purifying antibody
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
KR100857943B1
(ko)
|
2000-11-30 |
2008-09-09 |
메다렉스, 인코포레이티드 |
인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류
|
US6884869B2
(en)
|
2001-04-30 |
2005-04-26 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
US6441163B1
(en)
|
2001-05-31 |
2002-08-27 |
Immunogen, Inc. |
Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
|
WO2003011878A2
(fr)
|
2001-08-03 |
2003-02-13 |
Glycart Biotechnology Ag |
Variants de glycosylation d'anticorps presentant une cytotoxicite cellulaire accrue dependante des anticorps
|
WO2003026577A2
(fr)
|
2001-09-24 |
2003-04-03 |
Seattle Genetics, Inc. |
P-aminobenzyl ether dans des agents d'administration de medicaments
|
US7091186B2
(en)
|
2001-09-24 |
2006-08-15 |
Seattle Genetics, Inc. |
p-Amidobenzylethers in drug delivery agents
|
WO2003035835A2
(fr)
|
2001-10-25 |
2003-05-01 |
Genentech, Inc. |
Compositions de glycoproteine
|
AU2002363939A1
(en)
|
2001-11-20 |
2003-06-10 |
Seattle Genetics, Inc. |
Treatment of immunological disorders using anti-cd30 antibodies
|
US20040093621A1
(en)
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
US20040132140A1
(en)
|
2002-04-09 |
2004-07-08 |
Kyowa Hakko Kogyo Co., Ltd. |
Production process for antibody composition
|
CA2481656A1
(fr)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Cellules dans lesquelles l'activite de la proteine impliquee dans le transport du gdp-fucose est reduite ou perdue
|
US20040110704A1
(en)
|
2002-04-09 |
2004-06-10 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells of which genome is modified
|
US7691568B2
(en)
|
2002-04-09 |
2010-04-06 |
Kyowa Hakko Kirin Co., Ltd |
Antibody composition-containing medicament
|
AU2003236018A1
(en)
|
2002-04-09 |
2003-10-20 |
Kyowa Hakko Kirin Co., Ltd. |
METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
|
EP1502603A4
(fr)
|
2002-04-09 |
2006-12-13 |
Kyowa Hakko Kogyo Kk |
MEDICAMENT CONTENANT UNE COMPOSITION D'ANTICORPS APPROPRIEE AU PATIENT SOUFFRANT DE POLYMORPHISME FC gammma RIIIA
|
WO2003102157A2
(fr)
|
2002-06-03 |
2003-12-11 |
Genentech, Inc. |
Bibliotheques de phages et anticorps synthetiques
|
WO2004032828A2
(fr)
|
2002-07-31 |
2004-04-22 |
Seattle Genetics, Inc. |
Conjugues anticorps anti-cd20-medicament pour le traitement du cancer et des troubles immunitaires
|
EP1545613B9
(fr)
|
2002-07-31 |
2012-01-25 |
Seattle Genetics, Inc. |
Conjugues d'auristatine et leur utilisation dans le traitement du cancer, d'une maladie auto-immune ou d'une maladie infectieuse
|
ES2361739T3
(es)
|
2002-08-16 |
2011-06-21 |
Immunogen, Inc. |
Reticulantes con elevada reactividad y solubilidad y su uso en la preparación de conjugados para el suministro dirigido de fármacos de molécula pequeña.
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
CN103833854B
(zh)
|
2002-12-16 |
2017-12-12 |
健泰科生物技术公司 |
免疫球蛋白变体及其用途
|
WO2004065416A2
(fr)
|
2003-01-16 |
2004-08-05 |
Genentech, Inc. |
Banques de phages anticorps synthetiques
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
CA2520898C
(fr)
|
2003-03-31 |
2009-10-20 |
Council Of Scientific And Industrial Research |
Pyrrolo(2,1-c)(1,4)benzodiazepines non-reticulees comme agents anticancereux potentiels et leur procede de preparation
|
US7755007B2
(en)
|
2003-04-17 |
2010-07-13 |
K&H Manufacturing, Inc |
Heated pet mat
|
US7276497B2
(en)
|
2003-05-20 |
2007-10-02 |
Immunogen Inc. |
Cytotoxic agents comprising new maytansinoids
|
ES2538469T3
(es)
|
2003-06-05 |
2015-06-22 |
Genentech, Inc. |
Terapia de combinación para trastornos de células B
|
EP2322547A1
(fr)
|
2003-06-25 |
2011-05-18 |
Crucell Holland B.V. |
Lectin specifique de cellules myeloides
|
GB0321295D0
(en)
|
2003-09-11 |
2003-10-15 |
Spirogen Ltd |
Synthesis of protected pyrrolobenzodiazepines
|
CA2542046A1
(fr)
|
2003-10-08 |
2005-04-21 |
Kyowa Hakko Kogyo Co., Ltd. |
Composition proteique hybride
|
CA2542125A1
(fr)
|
2003-10-09 |
2005-04-21 |
Kyowa Hakko Kogyo Co., Ltd. |
Procede permettant de produire une composition d'anticorps par inhibition par l'arn de la fonction de .alpha.1,6-fucosyltransferase
|
US7511032B2
(en)
|
2003-10-22 |
2009-03-31 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto
|
SI2380911T1
(en)
|
2003-11-05 |
2018-07-31 |
Roche Glycart Ag |
ANTIGEN-RELATED PATIENTS WITH INCREASED ATTENTION ON THE RECEPTOR FC AND EFFECTORAL FUNCTION
|
SG195524A1
(en)
|
2003-11-06 |
2013-12-30 |
Seattle Genetics Inc |
Monomethylvaline compounds capable of conjugation to ligands
|
WO2005053742A1
(fr)
|
2003-12-04 |
2005-06-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Medicament contenant une composition a base d'anticorps
|
WO2005082023A2
(fr)
|
2004-02-23 |
2005-09-09 |
Genentech, Inc. |
Liants et conjugues heterocycliques auto-immolateurs
|
GB0404577D0
(en)
|
2004-03-01 |
2004-04-07 |
Spirogen Ltd |
Pyrrolobenzodiazepines
|
WO2005085260A1
(fr)
|
2004-03-09 |
2005-09-15 |
Spirogen Limited |
Pyrrolobenzodiazepines
|
ES2527292T3
(es)
|
2004-03-31 |
2015-01-22 |
Genentech, Inc. |
Anticuerpos anti-TGF-beta humanizados
|
US7785903B2
(en)
|
2004-04-09 |
2010-08-31 |
Genentech, Inc. |
Variable domain library and uses
|
CA2885854C
(fr)
|
2004-04-13 |
2017-02-21 |
F. Hoffmann-La Roche Ag |
Anticorps anti-p-selectine
|
KR20120064120A
(ko)
|
2004-06-01 |
2012-06-18 |
제넨테크, 인크. |
항체 약물 접합체 및 방법
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
SI1791565T1
(sl)
|
2004-09-23 |
2016-08-31 |
Genentech, Inc. |
Cisteinsko konstruirana protitelesa in konjugati
|
US20100111856A1
(en)
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
EP3050963B1
(fr)
|
2005-03-31 |
2019-09-18 |
Chugai Seiyaku Kabushiki Kaisha |
Procédé pour la production de polypeptide au moyen de la régulation d'un ensemble
|
WO2006114115A1
(fr)
|
2005-04-26 |
2006-11-02 |
Trion Pharma Gmbh |
Combinaison d'anticorps et de glucocorticoides destinee au traitement du cancer
|
US8219149B2
(en)
|
2005-06-29 |
2012-07-10 |
Nokia Corporation |
Mobile communication terminal
|
WO2007008603A1
(fr)
|
2005-07-07 |
2007-01-18 |
Seattle Genetics, Inc. |
Composes de monomethylvaline presentant des modifications de la chaine laterale de phenylalanine au niveau de l'extremite c
|
US8871720B2
(en)
|
2005-07-07 |
2014-10-28 |
Seattle Genetics, Inc. |
Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
|
JP5686953B2
(ja)
|
2005-10-11 |
2015-03-18 |
アムゲン リサーチ (ミュンヘン) ゲーエムベーハー |
交差種特異的(cross−species−specific)抗体を含む組成物および該組成物の使用
|
WO2007056441A2
(fr)
|
2005-11-07 |
2007-05-18 |
Genentech, Inc. |
Polypeptides de liaison comprenant des sequences diversifiees et des sequences consensus hypervariables vh/vl
|
WO2007064919A2
(fr)
|
2005-12-02 |
2007-06-07 |
Genentech, Inc. |
Polypeptides de liaison avec des sequences de diversite limitees
|
PL1813614T3
(pl)
|
2006-01-25 |
2012-03-30 |
Sanofi Sa |
Środki cytotoksyczne zawierające nowe pochodne tomaymycyny
|
PT1999154E
(pt)
|
2006-03-24 |
2013-01-24 |
Merck Patent Gmbh |
Domínios proteicos heterodiméricos modificados
|
CA2651567A1
(fr)
|
2006-05-09 |
2007-11-22 |
Genentech, Inc. |
Polypeptides de liaison a squelettes optimises
|
MX2008015524A
(es)
|
2006-06-12 |
2009-01-13 |
Trubion Pharmaceuticals Inc |
Proteinas de union multivalentes monocatenarias con funcion efectora.
|
JP2009541275A
(ja)
|
2006-06-22 |
2009-11-26 |
ノボ・ノルデイスク・エー/エス |
二重特異性抗体の生産
|
JP5622390B2
(ja)
|
2006-07-18 |
2014-11-12 |
サノフイ |
癌治療用対epha2アンタゴニスト抗体
|
WO2008027236A2
(fr)
|
2006-08-30 |
2008-03-06 |
Genentech, Inc. |
Anticorps multispécifiques
|
EP1914242A1
(fr)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Nouveau anticorps Anti-CD38 pour le traitement du cancer
|
US20080226635A1
(en)
|
2006-12-22 |
2008-09-18 |
Hans Koll |
Antibodies against insulin-like growth factor I receptor and uses thereof
|
ES2695047T3
(es)
|
2007-04-03 |
2018-12-28 |
Amgen Research (Munich) Gmbh |
Dominio de unión específico entre especies
|
US20100183615A1
(en)
|
2007-04-03 |
2010-07-22 |
Micromet Ag |
Cross-species-specific bispecific binders
|
TR201816277T4
(tr)
|
2007-04-03 |
2018-11-21 |
Amgen Res Munich Gmbh |
Çapraz-tür-spesifik bağlama alanı.
|
CN100592373C
(zh)
|
2007-05-25 |
2010-02-24 |
群康科技(深圳)有限公司 |
液晶显示面板驱动装置及其驱动方法
|
SI2019104T1
(sl)
|
2007-07-19 |
2013-12-31 |
Sanofi |
Citotoksična sredstva, ki obsegajo nove tomaimicinske derivate, in njihova terapevtska uporaba
|
US8536310B2
(en)
|
2007-10-17 |
2013-09-17 |
Arca Biopharma, Inc. |
Antibodies to CLL-1
|
EP2225275A4
(fr)
|
2007-11-28 |
2013-04-03 |
Medimmune Llc |
Formulation de protéine
|
BRPI0820604A2
(pt)
|
2007-12-21 |
2017-05-09 |
Genentech Inc |
método de purificação de um anticorpo cd20, cristal de um anticorpo cd20, composição e método destinado ao tratamento de uma condição ou doença associada ao cd20
|
MX350962B
(es)
|
2008-01-07 |
2017-09-27 |
Amgen Inc |
Metodo para fabricar moleculas heterodimericas de fragmentos cristalizables de anticuerpo, utilizando efectos electrostaticos de direccion.
|
US8742076B2
(en)
|
2008-02-01 |
2014-06-03 |
Genentech, Inc. |
Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods
|
AR072804A1
(es)
|
2008-07-15 |
2010-09-22 |
Genentech Inc |
Conjugados derivados de antraciclina,proceso para su preparacion,composiciones farmaceuticas que los contienen y su uso como agentes antitumorales.
|
WO2010077643A1
(fr)
|
2008-12-08 |
2010-07-08 |
Tegopharm Corporation |
Ligands de masquage pour inhibition réversible de composés polyvalents
|
RU2683325C2
(ru)
|
2009-02-05 |
2019-03-28 |
Иммьюноджен, Инк. |
Новые производные бензодиазепина
|
BRPI1012560A2
(pt)
|
2009-04-01 |
2016-07-26 |
Genentech Inc |
anticorpos anti-fcrh5 e imunoconjugados e métodos de uso
|
AU2010234334B2
(en)
|
2009-04-08 |
2014-10-09 |
Deutsches Krebsforschungszentrum |
Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy
|
KR102010827B1
(ko)
|
2009-06-26 |
2019-08-14 |
리제너론 파마슈티칼스 인코포레이티드 |
천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
GB0920127D0
(en)
|
2009-11-17 |
2009-12-30 |
Ucb Pharma Sa |
Antibodies
|
US20130129723A1
(en)
|
2009-12-29 |
2013-05-23 |
Emergent Product Development Seattle, Llc |
Heterodimer Binding Proteins and Uses Thereof
|
WO2011090762A1
(fr)
|
2009-12-29 |
2011-07-28 |
Emergent Product Development Seattle, Llc |
Protéines de liaison hétérodimères et utilisations de celles-ci
|
JP2013519392A
(ja)
|
2010-02-16 |
2013-05-30 |
メディミューン,エルエルシー |
Hsa関連組成物および使用方法
|
JP5972864B2
(ja)
|
2010-04-15 |
2016-08-17 |
メディミューン リミテッド |
ピロロベンゾジアゼピン及びそれらのコンジュゲート
|
SG10201800757TA
(en)
|
2010-04-20 |
2018-02-27 |
Genmab As |
Heterodimeric antibody fc-containing proteins and methods for production thereof
|
TWI586806B
(zh)
|
2010-04-23 |
2017-06-11 |
建南德克公司 |
異多聚體蛋白質之製造
|
CA2797981C
(fr)
|
2010-05-14 |
2019-04-23 |
Rinat Neuroscience Corporation |
Proteines heterodimeriques et leurs procedes de production et de purification
|
AU2011265054B2
(en)
|
2010-06-08 |
2016-09-15 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
ES2402254T3
(es)
|
2010-09-30 |
2013-04-30 |
Heidelberg Pharma Ag |
Conjugados de amatoxinas con ligadores mejorados
|
MX352929B
(es)
|
2010-11-05 |
2017-12-13 |
Zymeworks Inc |
DISEÑO DE ANTICUERPOS HETERODIMÉRICOS ESTABLES CON MUTACIONES EN EL DOMINIO Fc.
|
ES2842937T3
(es)
|
2010-11-10 |
2021-07-15 |
Amgen Res Munich Gmbh |
Prevención de efectos adversos provocados por dominios de unión específicos de CD3
|
KR102244173B1
(ko)
|
2010-11-30 |
2021-04-26 |
추가이 세이야쿠 가부시키가이샤 |
세포상해 유도 치료제
|
JP6008864B2
(ja)
|
2010-12-02 |
2016-10-19 |
ナーヴィアノ メディカル サイエンシズ エス.アール.エル. |
モルホリニルアントラサイクリン誘導体の調製方法
|
EP2497499A1
(fr)
|
2011-03-10 |
2012-09-12 |
Heidelberg Pharma GmbH |
Conjugués d'amatoxine avec liens améliorés
|
EA028804B1
(ru)
|
2011-03-25 |
2018-01-31 |
Гленмарк Фармасьютикалс С.А. |
Гетеродимерные иммуноглобулины
|
WO2012130831A1
(fr)
|
2011-03-29 |
2012-10-04 |
Roche Glycart Ag |
Variants de fc d'anticorps
|
CN103796677B
(zh)
|
2011-04-20 |
2019-08-16 |
健玛保 |
针对her2和cd3的双特异性抗体
|
CN107936121B
(zh)
|
2011-05-16 |
2022-01-14 |
埃泰美德(香港)有限公司 |
多特异性fab融合蛋白及其使用方法
|
PL2714733T4
(pl)
|
2011-05-21 |
2019-08-30 |
Macrogenics, Inc. |
Cząsteczki wiążące CD3 zdolne do wiązania z ludzkim i nieludzkim CD3
|
EP2578230A1
(fr)
|
2011-10-04 |
2013-04-10 |
Trion Pharma Gmbh |
Élimination de cellules tumorales d'une récupération peropératoire de sang autologue
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
EP2750713B1
(fr)
|
2011-10-14 |
2015-09-16 |
Spirogen Sàrl |
Pyrrolobenzodiazépines et conjugués associés
|
WO2013101909A1
(fr)
|
2011-12-27 |
2013-07-04 |
Development Center For Biotechnology |
Anticorps bispécifique à chaîne légère pontée
|
AR090549A1
(es)
*
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
AR090903A1
(es)
|
2012-05-01 |
2014-12-17 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-pmel17
|
US9163090B2
(en)
|
2012-05-07 |
2015-10-20 |
Cellerant Therapeutics, Inc. |
Antibodies specific for CLL-1
|
US20150203591A1
(en)
|
2012-08-02 |
2015-07-23 |
Regeneron Pharmaceuticals, Inc. |
Mutivalent antigen-binding proteins
|
WO2014028560A2
(fr)
|
2012-08-14 |
2014-02-20 |
Ibc Pharmaceuticals, Inc. |
Anticorps bispécifiques redirigés contre des cellules t pour le traitement de maladies
|
WO2014043403A1
(fr)
|
2012-09-12 |
2014-03-20 |
Agensys, Inc. |
Dérivés d'amatoxine et conjugués à base de ceux-ci, à perméabilité cellulaire, en tant qu'inhibiteurs de l'arn polymérase
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
CA2889681C
(fr)
|
2012-09-27 |
2023-04-11 |
Merus B.V. |
Anticorps bispecifiques de type igg comme activateurs de lymphocytes t
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
JO3529B1
(ar)
|
2013-02-08 |
2020-07-05 |
Amgen Res Munich Gmbh |
مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
|
EP2774624A1
(fr)
|
2013-03-04 |
2014-09-10 |
Heidelberg Pharma GmbH |
Dérivés d'amatoxine
|
SG11201507214SA
(en)
|
2013-03-13 |
2015-10-29 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
EP3721902A1
(fr)
|
2013-03-14 |
2020-10-14 |
The Scripps Research Institute |
Ciblage de conjugués d'anticorps d'agent et leurs utilisations
|
EP3686217A1
(fr)
|
2013-03-15 |
2020-07-29 |
GlaxoSmithKline Intellectual Property (No.2) Limited |
Formulations d'anticorps à faibles concentrations
|
JP2016520600A
(ja)
|
2013-05-28 |
2016-07-14 |
ヌマブ アクチェンゲゼルシャフト |
新規抗体
|
TWI582111B
(zh)
|
2013-05-28 |
2017-05-11 |
高雄醫學大學 |
一種可屏蔽抗體活性的閉鎖器
|
TWI725931B
(zh)
|
2013-06-24 |
2021-05-01 |
美商建南德克公司 |
抗fcrh5抗體
|
CA2917886A1
(fr)
|
2013-07-12 |
2015-01-15 |
Zymeworks Inc. |
Constructions de liaison aux antigenes cd19 et cd3 bispecifiques
|
AU2014307080B2
(en)
|
2013-08-12 |
2018-06-07 |
Genentech, Inc. |
1-(chloromethyl)-2,3-dihydro-1H-benzo(E)indole dimer antibody-drug conjugate compounds, and methods of use and treatment
|
EP3176185A1
(fr)
|
2013-11-04 |
2017-06-07 |
Glenmark Pharmaceuticals S.A. |
Production lymphocytes t de reciblage d'immunoglobulines hétéro-dimères
|
JP6681838B2
(ja)
|
2013-12-16 |
2020-04-15 |
ジェネンテック, インコーポレイテッド |
ペプチド模倣薬化合物及びその抗体−薬剤複合体
|
MX371092B
(es)
|
2013-12-16 |
2020-01-16 |
Genentech Inc |
Compuestos peptidomimeticos y conjugados de anticuerpo-farmaco de los mismos.
|
JP6980384B2
(ja)
|
2013-12-16 |
2021-12-15 |
ジェネンテック, インコーポレイテッド |
1−(クロロメチル)−2,3−ジヒドロ−1h−ベンゾ[e]インドール二量体抗体−薬物コンジュゲート化合物、並びに使用及び処置の方法
|
CN107106700B
(zh)
|
2013-12-16 |
2020-10-30 |
基因泰克公司 |
肽模拟化合物及其抗体-药物缀合物
|
PE20210107A1
(es)
|
2013-12-17 |
2021-01-19 |
Genentech Inc |
Anticuerpos anti-cd3 y metodos de uso
|
AU2014364601A1
(en)
|
2013-12-17 |
2016-07-07 |
Genentech, Inc. |
Methods of treating HER2-positive cancers using PD-1 axis binding antagonists and anti-HER2 antibodies
|
TWI701042B
(zh)
|
2014-03-19 |
2020-08-11 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
GB201409653D0
(en)
|
2014-05-30 |
2014-07-16 |
Stell Dr Anneliese |
Pyrrolobenzodiazepine therapeutic agents
|
MY179611A
(en)
|
2014-08-04 |
2020-11-11 |
Hoffmann La Roche |
Bispecific t cell activating antigen binding molecules
|
WO2016019969A1
(fr)
|
2014-08-08 |
2016-02-11 |
Ludwig-Maximilians-Universität München |
Anticorps bispécifiques administrés par voie sous-cutanée, destinés à être utilisés dans le traitement du cancer
|
WO2016036678A1
(fr)
|
2014-09-02 |
2016-03-10 |
Medimmune, Llc |
Formulations d'anticorps bispécifiques
|
MA40579A
(fr)
|
2014-09-12 |
2016-03-17 |
Genentech Inc |
Anticorps anti-cll-1 et immunoconjugués
|
CA2959689A1
(fr)
|
2014-09-17 |
2016-03-24 |
Genentech, Inc. |
Pyrrolobenzodiazepines et conjugues a base de disulfure d'anticorps associes
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
MX2017006312A
(es)
|
2014-11-17 |
2017-08-21 |
Regeneron Pharma |
Metodos para el tratamiento tumoral utilizando el anticuerpo biespecifico cd3xcd20.
|
AU2015358532C1
(en)
|
2014-12-03 |
2020-10-29 |
Genentech, Inc. |
Quaternary amine compounds and antibody-drug conjugates thereof
|
JP6802158B2
(ja)
|
2014-12-05 |
2020-12-16 |
ジェネンテック, インコーポレイテッド |
抗CD79b抗体及び使用方法
|
CN107660214B
(zh)
|
2015-01-08 |
2022-02-08 |
根马布股份公司 |
针对cd3和cd20的双特异性抗体
|
EP3778640A1
(fr)
|
2015-05-01 |
2021-02-17 |
Genentech, Inc. |
Anticorps anti-cd3 masqués et leurs procédés d'utilisation
|
JP6810058B2
(ja)
|
2015-05-28 |
2021-01-06 |
ジェネンテック, インコーポレイテッド |
抗cd3ホモ二量体を検出するための細胞に基づくアッセイ
|
WO2016204966A1
(fr)
|
2015-06-16 |
2016-12-22 |
Genentech, Inc. |
Anticorps anti-cd3 et leurs méthodes d'utilisation
|
JP6996983B2
(ja)
|
2015-06-16 |
2022-02-21 |
ジェネンテック, インコーポレイテッド |
抗cll-1抗体及び使用方法
|
MY189840A
(en)
|
2015-06-16 |
2022-03-11 |
Genentech Inc |
Humanized and affinity matured antibodies to fcrh5 and methods of use
|
AU2016280159A1
(en)
|
2015-06-17 |
2017-12-07 |
Genentech, Inc. |
Anti-HER2 antibodies and methods of use
|
EP3408671B1
(fr)
|
2016-01-25 |
2023-11-01 |
F. Hoffmann-La Roche AG |
Méthodes de dosage d'anticorps bispécifiques dépendants des lymphocytes t
|
US11466094B2
(en)
|
2016-11-15 |
2022-10-11 |
Genentech, Inc. |
Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies
|